Scholarlink

Purpose <p>To evaluate whether baseline anxiety–depressive symptom burden is associated with 3-month pain response after venous interventions in women with venous-origin chronic pelvic pain related to pelvic venous disorders (PeVD).</p> Materials and Methods <p>This single-center observational cohort study was a retrospective analysis of prospectively collected institutional registry data. A total of 103 women with symptomatic PeVD and venous-origin chronic pelvic pain who underwent venous intervention were included. Pain was assessed using a 0–10 numerical rating scale for average pelvic pain, disease-specific quality of life using the Pelvic Varicose Veins Questionnaire (PVVQ), and anxiety–depressive symptoms using the Hospital Anxiety and Depression Scale (HADS) and Beck Depression Inventory (BDI). Outcomes were assessed at baseline and 3&#xa0;months. Good pain response was defined as a ≥ 50% reduction in VAS score. Spearman correlation, multivariable linear regression, and Firth bias-reduced logistic regression were used.</p> Results <p>Baseline VAS, PVVQ, BDI, HADS-A, and HADS-D scores were 7.41 ± 0.90, 63.77 ± 11.76, 16.95 ± 8.70, 10.97 ± 3.15, and 8.94 ± 3.55, respectively. Clinically relevant anxiety symptoms (HADS-A ≥ 8), depressive symptoms (HADS-D ≥ 8), and BDI-defined depressive symptoms (BDI ≥ 14) were present in 80 (77.7%), 63 (61.2%), and 61 (59.2%) patients, respectively. At 3&#xa0;months, VAS decreased to 2.46 ± 2.55, PVVQ to 33.47 ± 17.74, BDI to 8.60 ± 9.55, HADS-A to 4.87 ± 4.79, and HADS-D to 4.90 ± 4.74 (all <i>P</i> &lt; 0.001). Good pain response occurred in 80 patients (77.7%). Baseline BDI correlated with VAS improvement percentage (<i>ρ</i> = − 0.792, 95% CI − 0.855 to − 0.707, <i>P</i> &lt; 0.001). After adjustment for age and baseline VAS, each one-point increase in baseline BDI was associated with a 2.98-percentage-point lower VAS improvement (95% CI − 3.38 to − 2.57, <i>P</i> &lt; 0.001) and higher odds of poor pain response (adjusted OR 1.94, 95% CI 1.21–3.13, <i>P</i> = 0.006).</p> Conclusion <p>Venous intervention was associated with significant 3-month improvement in pain, disease-specific quality of life, and anxiety–depressive symptoms. Greater baseline depressive symptom burden was associated with less favorable short-term pain response. These findings are exploratory and require validation in multicenter studies with standardized PeVD phenotyping and longer follow-up.</p> Graphical Abstract <p></p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Anxiety–Depressive Symptoms and Pain Response Following Venous Interventions for Venous-Origin Chronic Pelvic Pain Related to Pelvic Venous Disorders

  • 期刊论文

  • 发表日期：

    2026年7月20日

查看全文
  • Xiangtao Li,
  • Zongxu Jing,
  • Shuo Shan,
  • Lu Hu,
  • Xiaoyun Luo

摘要

Purpose

To evaluate whether baseline anxiety–depressive symptom burden is associated with 3-month pain response after venous interventions in women with venous-origin chronic pelvic pain related to pelvic venous disorders (PeVD).

Materials and Methods

This single-center observational cohort study was a retrospective analysis of prospectively collected institutional registry data. A total of 103 women with symptomatic PeVD and venous-origin chronic pelvic pain who underwent venous intervention were included. Pain was assessed using a 0–10 numerical rating scale for average pelvic pain, disease-specific quality of life using the Pelvic Varicose Veins Questionnaire (PVVQ), and anxiety–depressive symptoms using the Hospital Anxiety and Depression Scale (HADS) and Beck Depression Inventory (BDI). Outcomes were assessed at baseline and 3 months. Good pain response was defined as a ≥ 50% reduction in VAS score. Spearman correlation, multivariable linear regression, and Firth bias-reduced logistic regression were used.

Results

Baseline VAS, PVVQ, BDI, HADS-A, and HADS-D scores were 7.41 ± 0.90, 63.77 ± 11.76, 16.95 ± 8.70, 10.97 ± 3.15, and 8.94 ± 3.55, respectively. Clinically relevant anxiety symptoms (HADS-A ≥ 8), depressive symptoms (HADS-D ≥ 8), and BDI-defined depressive symptoms (BDI ≥ 14) were present in 80 (77.7%), 63 (61.2%), and 61 (59.2%) patients, respectively. At 3 months, VAS decreased to 2.46 ± 2.55, PVVQ to 33.47 ± 17.74, BDI to 8.60 ± 9.55, HADS-A to 4.87 ± 4.79, and HADS-D to 4.90 ± 4.74 (all P < 0.001). Good pain response occurred in 80 patients (77.7%). Baseline BDI correlated with VAS improvement percentage (ρ = − 0.792, 95% CI − 0.855 to − 0.707, P < 0.001). After adjustment for age and baseline VAS, each one-point increase in baseline BDI was associated with a 2.98-percentage-point lower VAS improvement (95% CI − 3.38 to − 2.57, P < 0.001) and higher odds of poor pain response (adjusted OR 1.94, 95% CI 1.21–3.13, P = 0.006).

Conclusion

Venous intervention was associated with significant 3-month improvement in pain, disease-specific quality of life, and anxiety–depressive symptoms. Greater baseline depressive symptom burden was associated with less favorable short-term pain response. These findings are exploratory and require validation in multicenter studies with standardized PeVD phenotyping and longer follow-up.

Graphical Abstract